Statin Combined with Amlodipine Treats Primary Aldosteronism
NCT ID: NCT06523465
Last Updated: 2024-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
180 participants
INTERVENTIONAL
2024-09-10
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
NCT07137364
Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism
NCT04409431
Adrenal Artery Ablation for Primary Aldosteronism
NCT03653845
Adrenal Artery Ablation Treats Primary Aldosteronism
NCT03398785
The Plasma Metabolomics Profiling of Primary Aldosteronism
NCT06500000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simvastatin combined with Amlodipine besylate
after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Amlodipine besylate for 6 months
Simvastatin combined with Amlodipine besylate
6-month treatment of Simvastatin combined with Amlodipine besylate
Simvastatin combined with Spironolactone and Amlodipine besylate.
after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Spironolactone and Amlodipine besylate for 6 months
Simvastatin combined with Spironolactone and Amlodipine besylate.
6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
Amlodipine besylate combined with Spironolactone
after 1:1 randomization, 60 patients with primary aldosteronism were treated with Amlodipine besylate combined with Spironolactone for 6 months
Amlodipine besylate combined Spironolactone
6-month treatment of Amlodipine besylate combined with Spironolactone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simvastatin combined with Amlodipine besylate
6-month treatment of Simvastatin combined with Amlodipine besylate
Simvastatin combined with Spironolactone and Amlodipine besylate.
6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
Amlodipine besylate combined Spironolactone
6-month treatment of Amlodipine besylate combined with Spironolactone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy
* Severe liver and kidney dysfunction
* Mental illness
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Military Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiming Zhu
Department of Hypertension and Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STOP-PA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.